Skip to content

Released May 9, 2023, after the close

10-Q filed May 9, 2023, 39 days after period end · 0000950170-23-019721

Q1 2023 · 10-Q
Revenue$175.20M+64.6% vs Q1 2022+43.3% vs Q4 2022
Net Income-$60.94MN/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$1.71N/M vs Q1 2022no prior Q4 2022 on file
Gross Profit$110,329,000+41.3%
Operating Income-$59,714,000N/M
Operating Cash Flow-$34,020,000N/M
Free Cash Flowderived-$45,492,000N/M
Margins · derived
Gross margin63.0%−10.4 pt vs Q1 2022
Operating margin-34.1%−31.2 pt vs Q1 2022
Net margin-34.8%−30.6 pt vs Q1 2022

What the release said

The release

Same quarter

MetricQ1 2023Q1 2022Q1 2021Q1 2020
Revenue$175.20M$106.42M$105.59M$104.82M
Net Income-$60.94M-$4.46M-$5.82M$25.67M
EPS Diluted-$1.71-$0.22-$0.30$1.32

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR